Dynavax launches Heplisav-B in the U.S.

Dynavax Technologies Corp. (NASDAQ:DVAX) launched Heplisav-B in the U.S. to prevent infection caused by all known subtypes of HBV in adults. Heplisav-B combines hepatitis B surface antigen (HBsAg) with a toll-like receptor 9 (TLR9) agonist. According to Dynavax, it is the only two-dose HBV vaccine approved in the U.S. for adults. ...